TY - JOUR
T1 - Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma
AU - Kari, Laszlo
AU - Loboda, Andrey
AU - Nebozhyn, Michael
AU - Rook, Alain H.
AU - Vonderheid, Eric C.
AU - Nichols, Calen
AU - Virok, Dezso
AU - Chang, Celia
AU - Horng, Wen Hwai
AU - Johnston, James
AU - Wysocka, Maria
AU - Showe, Michael K.
AU - Showe, Louise C.
PY - 2003/6/2
Y1 - 2003/6/2
N2 - We have used cDNA arrays to investigate gene expression patterns in peripheral blood mononuclear cells from patients with leukemic forms of cutaneous T cell lymphoma, primarily Sezary syndrome (SS). When expression data for patients with high blood tumor burden (Sezary cells >60% of the lymphocytes) and healthy controls are compared by Student's t test, at P > 0.01, we find 385 genes to be differentially expressed. Highly overexpressed genes include Th2 cells-specific transcription factors Gata-3 and Jun B, as well as integrin β1, proteoglycan 2, the RhoB oncogene, and dual specificity phosphatase 1. Highly underexpressed genes include CD26, Stat-4, and the IL-1 receptors. Message for plastin-T, not normally expressed in lymphoid tissue, is detected only in patient samples and may provide a new marker for diagnosis. Using penalized discriminant analysis, we have identified a panel of eight genes that can distinguish SS in patients with as few as 5% circulating tumor cells. This suggests that, even in early disease, Sezary cells produce chemokines and cytokines that induce an expression profile in the peripheral blood distinctive to SS. Finally, we show that using 10 genes, we can identify a class of patients who will succumb within six months of sampling regardless of their tumor burden.
AB - We have used cDNA arrays to investigate gene expression patterns in peripheral blood mononuclear cells from patients with leukemic forms of cutaneous T cell lymphoma, primarily Sezary syndrome (SS). When expression data for patients with high blood tumor burden (Sezary cells >60% of the lymphocytes) and healthy controls are compared by Student's t test, at P > 0.01, we find 385 genes to be differentially expressed. Highly overexpressed genes include Th2 cells-specific transcription factors Gata-3 and Jun B, as well as integrin β1, proteoglycan 2, the RhoB oncogene, and dual specificity phosphatase 1. Highly underexpressed genes include CD26, Stat-4, and the IL-1 receptors. Message for plastin-T, not normally expressed in lymphoid tissue, is detected only in patient samples and may provide a new marker for diagnosis. Using penalized discriminant analysis, we have identified a panel of eight genes that can distinguish SS in patients with as few as 5% circulating tumor cells. This suggests that, even in early disease, Sezary cells produce chemokines and cytokines that induce an expression profile in the peripheral blood distinctive to SS. Finally, we show that using 10 genes, we can identify a class of patients who will succumb within six months of sampling regardless of their tumor burden.
KW - cDNA microarrays
KW - Class prediction
KW - CTCL
KW - Discriminant analysis
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=12444335268&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12444335268&partnerID=8YFLogxK
U2 - 10.1084/jem.20021726
DO - 10.1084/jem.20021726
M3 - Article
C2 - 12782714
AN - SCOPUS:12444335268
SN - 0022-1007
VL - 197
SP - 1477
EP - 1488
JO - Journal of Experimental Medicine
JF - Journal of Experimental Medicine
IS - 11
ER -